Wandercraft Acquired Exoskeleton Firm Ekso Bionics
The merger unites robotic mobility developers to expand global market access and clinical distribution.
Updated on Oct. 1, 2026 in Healthcare
Live Poll
Do you trust that consolidation among medical robotics companies improves care options for patients?
Wandercraft completed its acquisition of Ekso Bionics from a subsidiary of ChronoScale Holdings Corporation on October 1, 2026. The deal combines the two companies' respective robotic mobility portfolios to scale global product distribution.
Why it matters
The acquisition aims to consolidate complementary clinical expertise and technology to drive broader international advocacy for medical exoskeleton coverage. Operators in the medical device space should note how this consolidation changes the competitive landscape for rehabilitation hardware.
The combined entity will support patients at more than 700 rehabilitation centers, building on a foundation that includes 150 facilities currently using the Atalante X system. While scale increases, the financial value of the deal remains undisclosed.
The players
Wandercraft
A developer of robotic exoskeleton technologies focused on mobility solutions for patients in rehabilitation settings.
Ekso Bionics
A designer and manufacturer of wearable robotic devices intended to assist in physical therapy and rehabilitation.
ChronoScale Holdings Corporation
The parent organization that held ownership of the Ekso Bionics subsidiary prior to the acquisition.
The details
The transaction was signed and closed simultaneously following unanimous approval by the boards of directors of both companies. Wandercraft plans to leverage a dedicated access team to help users navigate complex reimbursement pathways, specifically focusing on HCPCS code K1007. By integrating their clinical experience, the firms intend to accelerate the global adoption of robotic mobility solutions.
Timeline
The acquisition of Ekso Bionics closed on October 1, 2026.
Market Landscape
Medical technology companies are increasingly aligning their distribution strategies with specific reimbursement structures like Medicare HCPCS code K1007. This merger follows a broader trend of consolidations aimed at streamlining the complex documentation and financing requirements inherent in robotic orthotics.
Rehabilitation facility operators should monitor how this combined entity shifts its support for reimbursement documentation under code K1007. Review existing service agreements to see if changes in ownership impact current vendor support and training protocols.
The takeaway
The merger signals a move toward a more unified global standard for robotic mobility distribution. Management should track the combined company's upcoming advocacy initiatives regarding coverage, as these policy efforts often dictate the long-term viability of robotic physical therapy investments.
Further reading
For more on industry consolidation, see the Healthcare section.
Live Poll
Do you trust that consolidation among medical robotics companies improves care options for patients?
